Oral Candidiasis (Thrush): Causes, Symptoms, Treatment, and Prevention

Oral candidiasis, commonly called oral thrush, is a fungal infection of the mouth caused by Candida species, most commonly Candida albicans. Candida organisms are normally present in the mouth as part of the commensal microbial community in low numbers, held in check by the immune system, by competing bacteria, and by saliva's antifungal proteins. Infection develops when these control mechanisms are disrupted.

Oral candidiasis presents in several distinct clinical forms. Pseudomembranous candidiasis is the classic presentation: white, curd-like plaques on the tongue, inner cheeks, palate, or throat that can be wiped off, leaving a red or bleeding surface underneath. Erythematous candidiasis appears as flat red patches without white material, most often on the palate or tongue. Angular cheilitis, cracking and redness at the corners of the mouth, may involve Candida alone or in combination with Staphylococcus bacteria.

Chronic hyperplastic candidiasis appears as white patches that cannot be wiped off, which can resemble leukoplakia. This form requires biopsy to distinguish it from other white lesions, including some that carry malignant potential. Any non-removable white patch in the mouth should be evaluated by a dentist or oral medicine specialist.

Antibiotic use is one of the most common precipitating factors for oral candidiasis in otherwise healthy adults. Broad-spectrum antibiotics disrupt the bacterial microbiome of the mouth (as well as the gut), removing organisms that normally compete with Candida for colonization space and nutrients. Without this competition, Candida can proliferate. Oral thrush following a course of antibiotics, particularly broad-spectrum agents or prolonged courses, is common enough that some clinicians prophylactically recommend antifungal treatment in high-risk patients.

Inhaled corticosteroids used for asthma and COPD deposit residual drug in the oropharynx, suppressing local immune function and allowing Candida to overgrow. This is a predictable and preventable complication: rinsing the mouth and gargling with water after each use of an inhaled corticosteroid significantly reduces the drug's residual concentration in the mouth and substantially reduces the risk of candidiasis.

Dry mouth (xerostomia) from any cause is a major predisposing factor because saliva contains antifungal proteins (histatin, lactoferrin, and mucins) that normally inhibit Candida adhesion and growth. Patients with Sjogren's syndrome, those on xerostomic medications, and post-radiation patients have markedly elevated rates of oral candidiasis, often requiring ongoing antifungal management as part of their routine care.

Denture-related stomatitis is a specific form of oral candidiasis affecting the tissue under a denture. It presents as diffuse redness and sometimes edema of the palatal mucosa beneath an upper denture and is present in roughly two-thirds of complete denture wearers to some degree. The acrylic denture surface provides a reservoir for Candida biofilm that is difficult to eliminate with oral hygiene alone.

Patients who wear dentures continuously, including during sleep, are at particularly high risk. The denture-bearing tissue is not exposed to saliva's antifungal activity and is under continuous low-grade occlusion that promotes a moist, warm environment favorable to fungal growth. Wearing dentures at night is a modifiable risk factor for persistent denture stomatitis.

Management of denture-related candidiasis requires treating both the patient and the denture. Antifungal medication treats the infected tissue, but without also eliminating Candida from the denture surface, reinfection is nearly certain. Dentures should be soaked in an antifungal agent (nystatin suspension or a dilute bleach solution for non-metal frameworks) while the patient is on treatment. Poorly fitting dentures that create areas of chronic trauma further increase the risk.

HIV/AIDS, particularly in advanced stages with low CD4 counts, is strongly associated with oral candidiasis. In the pre-antiretroviral era, oral thrush was one of the most common opportunistic infections in HIV-positive individuals and was sometimes the first clinical indicator prompting HIV testing. With modern antiretroviral therapy maintaining immune function, candidiasis rates in well-controlled HIV are much lower, though still elevated compared to the general population.

Systemic corticosteroids and other immunosuppressive medications used for autoimmune diseases, organ transplantation, and inflammatory conditions reduce T-cell-mediated immunity, which is the primary defense against fungal infections. Patients on prednisone, tacrolimus, mycophenolate, or similar agents need monitoring for oral candidiasis, particularly during periods of higher doses or during concurrent antibiotic use.

Uncontrolled diabetes impairs neutrophil function and alters the oral environment in ways that favor Candida proliferation. Poorly controlled blood sugar also promotes carbohydrate availability in saliva that supports fungal growth. Patients with new or unexplained oral candidiasis without an obvious precipitating cause warrant screening for undiagnosed diabetes.

The first-line treatment for localized oral candidiasis in immunocompetent patients is topical antifungal therapy. Nystatin suspension (swish and swallow), nystatin pastilles (lozenges), and clotrimazole troches are all effective. These require the drug to be held in contact with the affected tissue for as long as possible before swallowing, which means patients should not eat or drink for 30 minutes after use. Treatment duration is typically 7 to 14 days.

Systemic antifungal therapy with fluconazole is preferred when the infection is extensive, involves the esophagus, or occurs in an immunocompromised patient. Fluconazole is highly effective against Candida albicans but less so against some non-albicans species (particularly C. glabrata and C. krusei). Patients who do not respond to fluconazole may require culture and susceptibility testing to guide alternative antifungal selection.

Angular cheilitis affecting the corners of the mouth typically requires a combination antifungal and antibacterial treatment because both Candida and Staphylococcus may be involved. Topical nystatin-triamcinolone combination cream or a separate antifungal plus antibiotic approach may be prescribed depending on clinical assessment.

For patients with identifiable and modifiable risk factors, addressing those factors is the most durable preventive strategy. Rinsing after inhaled corticosteroids, removing dentures at night and soaking them appropriately, improving blood sugar control in diabetic patients, and staying hydrated all reduce the conditions that allow Candida to overgrow.

Dietary sugar reduction is a reasonable adjunct. Candida thrives on simple sugars, and a diet high in refined carbohydrates provides abundant substrate for fungal growth. This is not a cure, but it reduces the ecological advantage Candida holds in a compromised oral environment.

For patients on chronic xerostomic medications or with Sjogren's syndrome who experience recurrent candidiasis, periodic prophylactic antifungal treatment during high-risk periods (such as during antibiotic courses) may be warranted. Your dentist and physician can help decide whether this approach is appropriate for your situation. Regular dental visits are important for early detection and treatment of recurrent episodes before they become established.